3D Printed Drugs Market

“Growing Advancements In 3d Printing Technology And Rising Investments”

The growing advancements in 3D printing technology is one of the major factors driving the growth of the 3Dprinted drugs market.

For instance, in December 2017, Aprecia and Cycle Pharmaceuticals from Cambridge in the UK announced a partnership to develop and commercialize 3D printed tablets for orphan (rare) diseases using the ZipDose technology. 

In 2015, the Howard Hughes Medical Institute developed a molecular 3D printer for formulating new drugs by synthesizing blocks of small molecules from the basic chemical pattern.

In October 2020, researchers from China’s Sichuan University and Xiamen University have developed 3D printed self-adhesive bandages that are capable of delivering nerve-healing drugs.  The team’s fabricated gauze comprises two click-activated hydrogel layers and an inner-section which can be loaded with regenerative medicine. Once wrapped around the site of an injured nerve, the device releases the medication in a way that encourages the growth of glial cells in the Peripheral Nervous System (PNS). 

In the future, the scientists believe that their novel 3D printed dressing design, could assist doctors while they carry out widely-used nerve repair operations such as neurorrhaphy.

In addition, the rising investments to increase the research activities for the development of highly efficient 3D printed drugs are expected to boost the growth of the market during the forecast period. 

In December 2020, Triastek, a chinese 3D printing technology startup, raised $15 million in Series A funding to accelerate the research and development of its 3D printed drugs. The funding round was led by fund management company Dalton Venture, while other co-investors included Shanghai Tofflon Science, Technology Chairman Zheng Xiaodong, and Yunqi Partners. Triastek will use the funds for the research and development of its 3D printed medicines alongside registration applications in China and the US, and in the construction of a large-scale production line.

“Growing Prevalence of Epilepsy”

The 3D printed market is expected to grow further over the forecast period, owing to rising prevalence of epilepsy globally. For instance, according to the World Health Organization (WHO) January 2019 report, around 50 million people are affected by epilepsy worldwide. Moreover, it is estimated that around 2.4 million new cases of epilepsy are diagnosed every year, globally.

The average incidence of epilepsy each year in the U. S is estimated at 150,000 or 48 for every 100,000 people. The incidence of epilepsy is higher in young children and older adults. This means that epilepsy starts more often in these age groups. When the incidence of epilepsy is looked at over a lifetime, 1 in 26 people will develop epilepsy at sometime in their life.

The number of people with epilepsy, using prevalence numbers, ranges from 1.3 million to 2.8 million (or 5 to 8.4 for every 1,000 people). The estimate currently thought to be most accurate is 2.2 million people or 7.1 for every 1,000 people.

However, higher numbers of people report that they have active epilepsy, 8.4 out of 1,000 people. These numbers are even higher when people are asked if they have ever had epilepsy (called lifetime prevalence). 16.5 per 1,000 people reported that they had epilepsy at some point in their life.

In August 2015, Spritam became the first 3D-printed drug approved by US Food and Drug Administration (FDA) as a prescription adjunctive therapy for treating myoclonic seizures, partial onset seizures and primary generalised tonic-clonic seizures in patients with epilepsy.

About Us:

DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year, we have secured more than 100 unique customers from established organizations all over the world.

For more information:

Sai Kiran

Sales Manager at DataM Intelligence

Email: [email protected]

Tel: +1 877 441 4866

Website: www.datamintelligence.com